15% OFF YOUR FIRST ORDER · CODE 1stOrder
Research hub

Cartalax Peptide

Cartalax is a synthetic Ala-Glu-Asp tripeptide studied in preclinical research on short peptide bioregulators and cellular processes. Direct SARMs America provides Cartalax solely for use in laboratory research. Please browse the products available below:

CartalaxSynthetic PeptideTripeptide3 Amino AcidsLinear Structure
Molecular Weight
333.29 g/mol
Molecular Formula
C12H19N3O8
Purity
99.6%
Available nowCartalax Peptide · in stock, EU dispatch
Cartalax Peptide Vial
20mg
Price range: $51.88 through $63.10View
01

What Is Cartalax?

Cartalax is a synthetic tripeptide known chemically as alanyl-glutamyl-aspartic acid (Ala-Glu-Asp). The peptide contains three amino acid residues arranged in the AED sequence. Scientific records also identify it as the T-31 peptide and classify it as an oligopeptide.

The compound is a small peptide with a defined molecular structure and sequence. Its scientific identity is based on the Ala-Glu-Asp sequence which distinguishes Cartalax from other short peptide compounds with different amino acid arrangements.

02

Research Overview Table

Research OverviewCurrent Status
Compound ClassSynthetic short-chain tripeptide/peptide bioregulator (Ala-Glu-Asp; AED)
Primary Research TargetCartilage and connective-tissue biology; proposed effects on chondrocytes and gene-expression pathways
Published Cell StudiesAvailable
Published Animal StudiesAvailable, including animal research involving AED/T-31 and related cartilage peptide preparations
Controlled Human Clinical TrialsNo published controlled human clinical trials identified
Primary Research FieldCartilage biology, chondrocyte aging, chondrogenic differentiation, osteoarthritis research, and musculoskeletal tissue biology.
Research MaturityPredominantly preclinical
Intended UseLaboratory research only
03

Chemical and Molecular Characteristics

Chemical NameL-alanyl-L-glutamyl-L-aspartic acid
Compound NameCartalax
Compound TypeSynthetic tripeptide
Molecular FormulaC₁₂H₁₉N₃O₈
Molecular Weight333.29 g/mol
Purity99.6%
Batch Number2026070603
Primary Research TargetNot established
Product FormatLyophilized vials, nasal sprays, or pre-mixed injection pens
Physical PresentationSupplied as sterile lyophilized powder or pre-formulated liquid, depending on the selected product format

Cartalax is a linear tripeptide with an Ala-Glu-Asp sequence. Its structure contains three L-amino acid residues joined by peptide bonds. Glutamic acid and aspartic acid contribute additional carboxyl groups giving the molecule a strongly polar character. The structure is compact compared with longer peptides and does not contain the extended residue sequence or higher-order architecture found in larger peptide molecules.

The compound has several hydrogen bonding sites. It also has a high calculated polar surface area. These features contribute to its hydrophilic chemical profile.

Its structure is small and well defined. This sets it apart from larger research peptides, which may have more complex conformations. These molecular features matter when Cartalax is studied as a short, chemically defined peptide under controlled laboratory conditions.

Certificates:

CoAhttps://america.direct-sarms.com/wp-content/uploads/2026/09/Cartalax_COA.pdf
HPLChttps://america.direct-sarms.com/wp-content/uploads/2026/09/Cartalax_HPLC.pdf
04

Mechanism of Action Under Investigation

Cartalax has no confirmed receptor or enzyme target. Published research has instead examined DNA as a possible molecular target. In one study, Ala-Glu-Asp (AED) formed a favorable complex with an AT-rich DNA sequence in the minor groove. The reported interaction was associated with changes in gene expression linked to cellular aging.

The proposed interaction may affect DNA structure and in turn, transcriptional activity. Research has examined changes in p16, p21, p53, and SIRT6 following AED exposure. Other work found that AED can influence DNA duplex stability supporting further investigation of peptide-DNA interactions.

The exact molecular mechanism remains unresolved. Current studies do not establish a specific receptor, enzyme, binding affinity, or defined sequence-specific target for Cartalax. The available evidence supports continued investigation of peptide-DNA interaction and its relationship to changes in gene expression, but it does not establish a complete molecular pathway.

05

Scientific Research Context

Cartalax has a relatively small evidence base compared with extensively studied peptide compounds. The literature is primarily preclinical and includes in vitro research and animal studies. Research has developed through laboratory investigations rather than a broad clinical research program. Human evidence remains limited. Overall, the field is still at an exploratory stage, with the existing literature providing an early foundation for further investigation rather than a mature body of clinical evidence.

06

Cartalax Biology and Biological Pathways

01

Primary Biological Function

Published Cartalax research has mainly examined cell renewal, cellular aging, proliferation, apoptosis, and extracellular matrix regulation. These processes describe basic changes in cell number, survival, and tissue maintenance. They are relevant to research on how short peptides may influence cellular behavior during aging.

02

Relevant Metabolic or Signaling Pathways

The literature points to biological processes involving cell-cycle regulation, apoptosis, cellular senescence, and gene-expression control. Markers such as p16, p21, p53 and SIRT6 are connected with these processes. Their study helps researchers characterize changes in cellular state without assigning a therapeutic role to the peptide.

03

Tissue-Specific Biology

Research has examined Cartalax in kidney tissue and skin fibroblasts. Kidney studies have focused on cell renewal and aging-related cellular changes. Work with skin fibroblasts has examined proliferation, apoptosis and extracellular matrix remodeling. These tissues provide different biological settings for examining cellular responses to short peptides.

04

Experimental Biomarkers

Several biomarkers have been used to characterize these biological processes. Ki-67 is associated with cell proliferation. While p53, p16 and p21 are commonly examined in studies of cell-cycle control and cellular senescence. SIRT6 has also been evaluated in aging-related research. Other reported markers include CD98hc, caspase-3, and MMP-9, covering cellular renewal, apoptosis, and matrix remodeling.

05

Laboratory Investigation Methods

Researchers have used primary cell cultures, organotypic tissue cultures, immunofluorescence, confocal microscopy, gene-expression analysis, and molecular modeling to examine Cartalax-related biology. These methods allow different aspects of cellular regulation to be studied, from changes in protein markers to broader patterns of gene expression. Using several approaches provides a broader view of the biological processes under investigation.

07

Experimental Models Used in Published Research

Published Cartalax research has used several in vitro cellular and tissue-based systems, with some work involving animal-derived material. The available models are narrow in scope and do not provide a complete representation of human biology. These limitations matter when interpreting the research base and separating laboratory observations from broader biological conclusions.

01

Skin Fibroblast Cultures

Cultured skin fibroblasts have been used as an in vitro model of cellular aging. The main limitation is that isolated fibroblasts do not reproduce the full structure of skin or interactions among different cell types. Findings from this system therefore have limited relevance to whole-tissue biology.

02

Renal Tissue Cultures

Organotypic kidney tissue cultures from young and old rats have been used in published work. This model provides tissue-level organization that isolated cells lack. However, cultured kidney tissue does not reproduce normal blood flow, systemic regulation or interactions with other organs.

03

Renal Cell Cultures

Primary renal cell cultures have also been used to study Cartalax-related cellular processes. This approach allows controlled laboratory investigation of kidney-derived cells. Its main limitation is the loss of the three-dimensional tissue environment and systemic influences present in a living organism.

04

Human Mesenchymal Stem Cell Cultures

Human mesenchymal stem cells provide a human-derived cellular model for studying Cartalax in vitro. Their use avoids some species-related limitations of animal cells. However, cultured cells remain an artificial experimental setting and cannot reproduce the complex interactions, metabolism, and regulation occurring within intact human tissues.

08

Cartalax Published Research

01

Kidney Cell Aging

Researchers have studied Ala-Glu-Asp (AED), also identified as T-31, in primary kidney cell cultures during in-vitro aging. The work examined cellular renewal and changes in signaling markers, including Ki-67, p53, MMP-14, and IL-8. The study was designed to examine how T-31 relates to cellular processes that change during renal cell aging. The evidence is limited to cultured cells and does not establish the same biology in intact human kidney tissue.

02

Kidney Tissue Renewal

Another study investigated T-31 in organotypic kidney tissue cultures obtained from young and old rats. Researchers examined cellular renewal and apoptosis in the tissue cultures and compared responses to a renal polypeptide complex and the short peptides T-31 and T-35. The work provides ex vivo evidence from rat kidney tissue, but this model does not reproduce the systemic environment of a living organism.

03

Human Mesenchymal Stem Cell Aging

Researchers have also investigated AED in human mesenchymal stem-cell aging cultures. The study compared different cellular aging conditions and examined expression of IGF1, FOXO1, TERT, TNKS2, and NFκB after peptide exposure. This work extends AED research into a human-derived cell system, but the findings remain limited to cultured cells and do not establish corresponding changes in intact human tissues.

04

Kidney Injury Research

AED has also been included in research examining experimental kidney injury. One study investigated the kidney tripeptides T-31 and T-35 in a rat model of rhabdomyolysis-associated renal injury. Researchers examined processes related to tubular-cell injury, oxidative stress, and energy imbalance. This work adds an animal model to the literature, although its findings are limited by the experimental design and species differences.

09

Limitations of Current Research

01

Evidence Is Predominantly Preclinical

Cartalax research has mainly used cell cultures and animal-derived experimental systems. Published studies include primary kidney cells, organotypic kidney cultures, and rat-based models. Researchers have not yet built a large clinical evidence base around the compound. Most of the available literature therefore comes from early laboratory and preclinical work.

02

Human Clinical Evidence

The studies identified in the peer-reviewed literature include human-derived cell systems, such as mesenchymal stem-cell cultures, but these are not clinical studies. The available publications do not provide a substantial controlled human clinical evidence base for Cartalax. Conclusions about human biology therefore remain limited to what has been demonstrated in experimental systems.

03

Species Differences

Several investigations use Wistar rat cells or kidney tissue, while other work uses human cell cultures. Differences between species can affect cellular behavior and tissue responses. Findings from rat-derived systems therefore cannot be assumed to represent human biology. Human-cell experiments reduce this limitation but still do not reproduce an intact human tissue environment.

04

Study Design Limitations

The published studies use different experimental systems, including primary cells and organotypic tissue cultures. Such models allow controlled investigation but cannot reproduce the full physiological environment of a living organism. Differences in culture conditions and experimental design also make direct comparison between individual studies difficult.

05

Independent Replication

The Cartalax literature identified in research is relatively small, with several studies coming from closely related research groups. Independent replication across laboratories is limited. This makes it difficult to determine how consistently the reported observations can be reproduced under different experimental conditions.

10

Analytical Documentation

HPLC separates Cartalax from other substances in a sample and can determine peptide purity. LC-MS provides a mass measurement for comparison with the expected molecular weight. NMR can examine structural features when the sample is suitable for analysis. A Certificate of Analysis (CoA) records the results for a specific Cartalax batch, including purity and other specification data.

Each method addresses a different analytical point. HPLC examines separation and purity. LC-MS checks molecular mass. NMR provides structural information. The CoA documents the results obtained for the tested batch.

Analytical documentation confirms Cartalax identity and chemical quality. It does not establish biological performance.

11

Storage and Laboratory Handling

Store Cartalax according to the product-specific storage specifications. The supplied Certificate of Analysis lists storage at 2–8°C for the referenced batch. Laboratory personnel should handle the material using appropriate procedures and clean equipment. Keep the container closed when not in use and protect the material from contamination, moisture, and unsuitable storage conditions.

Cartalax from Direct Sarms America is intended for laboratory research use only. No dosage or administration information applies to this research material.

12

Frequently asked questions

Cartalax is a synthetic tripeptide made from alanine, glutamic acid, and aspartic acid. The peptide is also referred to as Ala-Glu-Asp or AED in published research. Studies have examined it in cellular aging and related areas of experimental biology. Current research mainly uses laboratory and preclinical systems.
13

Why choose us?

Direct SARMs America is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.

Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.

Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs America, we aim to make the research supply process simple, clear, and reliable.

Cartalax Peptide is supplied solely for laboratory research and analytical purposes. It is not intended for human or veterinary use, consumption, diagnosis, treatment, or any clinical application. Information provided on this page is for scientific reference only and should be considered alongside the cited primary literature and relevant analytical documentation.
Available now

Cartalax Peptide from Direct Sarms America

Cartalax Peptide Vial
20mg
Price range: $51.88 through $63.10View